Comparing The Cyberlink Control System to the Manual Letter Board for Communication Purposes in the ALS Patient Population
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00718497|
Recruitment Status : Completed
First Posted : July 18, 2008
Last Update Posted : March 5, 2013
New technologies are giving people with motor disabilities alternative communication and control channels. The investigators are interested in using the Cyberlink Control System as a hands free means to access a computer for people with Amyotrophic Lateral Sclerosis (ALS). The goal of this project is to determine whether this device is a practical and realistic means for ALS patients to communicate with only the use of facial muscle, brainwave, and eye movements.
The benefit of this study may be of substantial value to many people with severe motor impairment. Additionally, it is hoped that some of the study subjects may benefit by incorporating hands-free computer use into their daily lives.
This study is intended to evaluate the effectiveness of the cyberlink as a tool for daily communication compared to the standard manual letter board.
|Condition or disease|
|Amyotrophic Lateral Sclerosis Neurodegenerative Disease Motor Neuron Disease|
|Study Type :||Observational|
|Actual Enrollment :||25 participants|
|Official Title:||Comparing The Cyberlink Control System to the Manual Letter Board for Communication Purposes in the ALS Patient Population|
|Study Start Date :||August 2007|
|Actual Primary Completion Date :||May 2012|
|Actual Study Completion Date :||May 2012|
Subjects having either definite or probable ALS by El Escorial Criteria.
- Time Taken to Complete a Sentence [ Time Frame: 1 session ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00718497
|United States, Pennsylvania|
|MDA/ALS Center of Hope|
|Philadelphia, Pennsylvania, United States, 19107|
|Principal Investigator:||Terry Heiman-Patterson, MD||MDA/ALS Center of Hope|